SCHEMBL4394138

SCHEMBL4394138

[CH2]CCS(=O)(=O)c1ccc(C)cc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 1/20 0.43
RAPGEF4 Q8WZA2 1/20 0.42
ALDH1A1 P00352 7/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
ALOX12 P18054 1/20 0.41
GFER P55789 1/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.39
F2 P00734 1/20 0.39
PKM P14618 2/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4390836 0.89 ALDH1A1 (0.43) MEP1BRAPGEF4ALDH1A1MAPTHPGD
SCHEMBL11775829 0.85 HTT (0.42) ALDH1A1MAPTHPGDKMT2ASMN1; SMN2
SCHEMBL4398061 0.85 MEP1B (0.45) MEP1BRAPGEF4ALDH1A1MAPTHPGD
SCHEMBL10407448 0.83 RAPGEF4 (0.46) MEP1BRAPGEF4ALDH1A1MAPTHPGD
SCHEMBL7036105 0.81 MEP1B (0.43) MEP1BRAPGEF4ALDH1A1MAPTHPGD
SCHEMBL7034776 0.81 MEP1B (0.46) MEP1BRAPGEF4ALDH1A1MAPTHPGD
SCHEMBL10407436 0.80 RAPGEF4 (0.50) MEP1BRAPGEF4ALDH1A1MAPTHPGD
SCHEMBL3253706 0.80 MEP1B (0.47) MEP1BRAPGEF4ALDH1A1MAPTHPGD
SCHEMBL10407445 0.80 RAPGEF4 (0.44) MEP1BRAPGEF4ALDH1A1MAPTHPGD
SCHEMBL11340580 0.78 ALDH1A1 (0.40) MEP1BRAPGEF4ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306376-A1 OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME MITSUI CHEMICALS, INC. (JP) 2009-12-10 US disclosed
US-7405030-B2 Imide compound and optical recording media made by using the same MITSUI CHEMICALS, INC. (JP) 2008-07-29 US disclosed
EP-1930339-A2 Imide compound MITSUI CHEMICALS, INC. (JP) 2008-06-11 EP disclosed
US-20070259151-A1 Imide compound and optical recording media made by using the same MITSUI CHEMICALS, INC. (JP) 2007-11-08 US disclosed
US-7259260-B2 Imide compound and optical recording media made by using the same MITSUI CHEMICALS, INC. (JP) 2007-08-21 US disclosed
US-20070054084-A1 Optical recording medium and compound used for the same MITSUI CHEMICALS, INC. (JP) 2007-03-08 US disclosed
EP-1672626-A1 OPTICAL RECORDING MEDIUM AND COMPOUND USED IN THE OPTICAL RECORDING MEDIUM Mitsui Chemicals, Inc. (JP) 2006-06-21 EP disclosed
US-20050208425-A1 Imide compound and optical recording media made by using the same YAMAMOTO CHEMICALS, INC. (JP) 2005-09-22 US disclosed
EP-1445115-A1 IMIDE COMPOUNDS AND OPTICAL RECORDING MEDIA MADE BY USING THE SAME Mitsui Chemicals, Inc. (JP) 2004-08-11 EP disclosed
US-3976672-A INSECTICIDE UNIROYAL INC. (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306376-A1 OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME CACNA1B, KCNN4, KCNN2 MEP1B 918/4885RAPGEF4 501/4885ALDH1A1 4231/4885
US-20050208425-A1 Imide compound and optical recording media made by using the same CRY1, MTNR1A, TRPA1 MEP1B 1002/4885RAPGEF4 432/4885ALDH1A1 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.